| Literature DB >> 28701211 |
Dieter Benninghoven1,2, Denise Hamann3, Yskert von Kodolitsch3, Meike Rybczynski3, Julia Lechinger4, Friedrich Schroeder4, Marina Vogler5, Eike Hoberg4.
Abstract
BACKGROUND: Advances in medical, interventional and surgical treatment have increased average life expectancy of patients with congenital heart defects. As a result a new group of adult patients with congenital cardiac defects requires medical rehabilitation. Patients with Marfan syndrome (MFS) are a relevant group among these patients. So far, no reports on the effectiveness of specialized rehabilitation programmes for MFS patients exist. We implemented an inpatient 3-week rehabilitation program for MFS patients at the Muehlenberg-Clinic for rehabilitation and assessed the medical safety as well as the impact of the program on physical fitness and psychological wellbeing of participants by means of an observational pilot study. The comprehensive multidisciplinary program included medical, physiotherapeutic, psychological and social issues. Two groups including 8 and 10 individuals with verified MFS attended the programme. Medically adverse events that occurred during the rehabilitation were registered. Adverse events were defined as: any new cardiac arrhythmias such as atrial fibrillation, ventricular tachycardia, cardiac syncope or any complications located at the aorta. Psychological assessment was performed using Short Form-36 (SF-36), hospital anxiety and depression scale and other psychometric questionnaires. Medical examinations included assessment of maximum power in bicycle ergometry. All assessments were performed at the beginning and at the end of the rehabilitation. Psychometric assessments were repeated 1 year after the end of the programme for both groups, respectively.Entities:
Keywords: Congenital heart defect; Inpatient rehabilitation; Marfan syndrome; Multidisciplinary rehabilitation; Quality of life
Mesh:
Year: 2017 PMID: 28701211 PMCID: PMC5508759 DOI: 10.1186/s13023-017-0679-0
Source DB: PubMed Journal: Orphanet J Rare Dis ISSN: 1750-1172 Impact factor: 4.123
Sociodemographic data
| Variable | |
|---|---|
| Age | |
| m | 46.7 |
| sd | 7.8 |
| Years of school education | |
| m | 10.8 |
| sd | 1,5 |
| Gender (n) | |
| Female | 14 |
| Male | 4 |
| Professional Qualification (n) | |
| Blue collar | 2 |
| White collar | 16 |
| Marital Status (n) | |
| Single/no partner | 1 |
| Married | 15 |
| Divorced/Separated | 2 |
| Children (n) | |
| 0 | 7 |
| 1 | 2 |
| 2 | 8 |
| 3 | 1 |
m mean, sd standard deviation, n number of patients
Cardiovascular manifestations and surgical / pharmacological treatment
| Cardiovascular manifestations previously treated by surgery | Number of patients affected |
| mitral valve prolapse | 3 |
| tricuspid valve prolapse | 1 |
| aortic dissection stanford A | 1 |
| aortic dissection stanford B | 2 |
| aortic regurgitation | 7 |
| aortic aneurysma | 9 |
| mitral regurgitation | 2 |
| patent foramen ovale | 1 |
| pulmonary artery dilatation | 1 |
| Cardiovascular manifestations not yet treated by surgery | Number of patients affected |
| mild mitral valve prolapse | 1 |
| ascending aorta <45 mm | 2 |
| Corresponding medication | Number of patients treated with |
| angiotensin II receptor antagonist | 13 |
| beta 1 receptor blocker | 8 |
| aspirin | 4 |
| phenprocoumon | 4 |
| diuretics | 1 |
| calcium channel blocker | 2 |
| simvastatine | 2 |
| none (refused by patient) | 2 |
| Previous cardiovascular surgery | Number of patients treated with |
| david procedure | 6 |
| aortic valve replacement | 4 |
| mitral valve replacement | 1 |
| aortic prothesis | 5 |
| aortic valve reconstruction | 2 |
| mitral valve reconstruction | 2 |
| patent foramen ovale closure | 1 |
| Current NYHA functional classification | Number of patients |
| NYHA I | 12 |
| NYHA II | 6 |
NYHA functional classification: New York Heart Association functional classification
Analyses of admission to discharge differences in assessments of physical fitness by t-tests and effect-sizes (Cohen’s d)
| Admission | Discharge | Admission to discharge | ||||||
|---|---|---|---|---|---|---|---|---|
| Assessment parameter | m | sd | m | sd | na | t | p | Cohen’s |
| Maximum Watt per kg body weight for at least 20 min | .54 | .21 | .77 | .23 | 17 | 4.455 | <.001 | 1.1 |
| Maximum nordic walking distance in meter | 1694 | 893 | 2356 | 666 | 17 | 3.492 | <.05 | 0.8 |
m mean, sd standard deviation, n sample size, t-value in t-test for repeated measurements; p level of statistical significance, Cohen’s d: effect size of pre-post-differences
aData from 1 patient of the first cohort is missing
Analyses of admission-discharge and admission-follow-up differences in psychological assessments by t-tests for repeated measurements and effect-sizes (Cohen’s d)
| assessment scale | admission | discharge | admission to discharge | follow-up | admission to follow-up | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| m | sd | n | m | sd | na | T | p |
| M | sd | nb | T | p |
| |
| HADS Depression | 7.17 | 4.69 | 18 | 5.06 | 4.21 | 18 | 3.43 | <.05 | 0.5 | 5.0 | 4.47 | 16 | 2.38 | <.05 | 0.5 |
| HADS Anxiety | 9.61 | 5.26 | 18 | 6.67 | 5.42 | 18 | 4.17 | <.05 | 0.6 | 7.0 | 4.32 | 16 | 2.33 | <.05 | 0.5 |
| SCL-90-R Somatization | 23.1 | 7.80 | 18 | 20.6 | 6.36 | 18 | 2.14 | <.05 | 0.4 | 22.3 | 7.74 | 16 | −.1 | .922 | 0.1 |
| FSS | 5.62 | .91 | 18 | 5.14 | 1.10 | 18 | 2.45 | <.05 | 0.5 | 4,92 | 1.51 | 16 | 2.33 | <.05 | 0.6 |
| SF-36 physical functioning | 59.4 | 18.1 | 18 | 65.6 | 21.96 | 18 | −1.96 | .067 | 0.3 | 67.7 | 23.7 | 15 | −1.61 | .129 | 0.4 |
| SF-36 physical role functioning | 41.7 | 40.2 | 18 | 58.3 | 40.22 | 18 | −1.65 | .117 | 0.4 | 66,7 | 40.8 | 15 | −3.29 | <.05 | 0.6 |
| SF-36 bodily pain | 46.1 | 28.8 | 18 | 58.4 | 28.97 | 17 | −2.31 | <.05 | 0.4 | 51.2 | 25.7 | 15 | −1.14 | .272 | 0.2 |
| SF-36 general health perception | 41.3 | 15.4 | 18 | 47.1 | 15.52 | 18 | −1.81 | .089 | 0.4 | 48,6 | 19.0 | 14 | −1.52 | .154 | 0.4 |
| SF-36 vitality | 34.7 | 13.9 | 18 | 51.4 | 18.13 | 18 | −5.56 | <.001 | 1.0 | 42.3 | 21.0 | 15 | −1.79 | .096 | 0.4 |
| SF-36 social role functioning | 67.4 | 33.3 | 18 | 74.3 | 25.18 | 17 | −1.16 | .264 | 0.2 | 77.7 | 27.4 | 14 | −1.38 | .192 | 0.3 |
| SF-36 emotional role limitation | 59.3 | 45.1 | 18 | 74.5 | 40.02 | 17 | −1.94 | .070 | 0.4 | 75.6 | 38.8 | 15 | −1.42 | .178 | 0.4 |
| SF-36 mental health | 59.3 | 20.7 | 18 | 73.8 | 17.26 | 18 | −4.84 | <.001 | 0.8 | 66.9 | 20.5 | 14 | −1.96 | .071 | 0.4 |
| PCS-36 | 36.3 | 8.64 | 18 | 38.7 | 9.7 | 17 | −1.22 | .240 | 0.3 | 40.6 | 10.4 | 14 | −2.02 | .064 | 0.5 |
| MCS-36 | 43.4 | 13.3 | 18 | 50.1 | 10.5 | 17 | −4.13 | <.001 | 0.6 | 47.8 | 11.5 | 14 | −1.59 | .135 | 0.4 |
| NHP pain | 30.6 | 33.0 | 18 | 25.0 | 32.65 | 18 | .95 | .354 | 0.2 | 21,7 | 31.9 | 15 | .96 | .352 | 0.3 |
| NHP physical mobility | 19.4 | 16.2 | 18 | 16.7 | 19.17 | 18 | .89 | .386 | 0.2 | 11.7 | 18.0 | 15 | 1.52 | .150 | 0.5 |
| NHP emotional reaction | 28.4 | 26.7 | 18 | 14.8 | 24.10 | 18 | 3.42 | <.05 | 0.5 | 14.1 | 19.0 | 15 | 2.29 | <.05 | 0.6 |
| NHP energy | 48.2 | 40.0 | 18 | 29.6 | 35.95 | 18 | 2.15 | <.05 | 0.5 | 33.3 | 35.7 | 15 | 1.52 | .150 | 0.4 |
| NHP social isolation | 8.89 | 17.1 | 18 | 10.0 | 14.14 | 18 | −.56 | .579 | −0.1 | 13.3 | 19.5 | 15 | −.81 | .433 | −0.2 |
| NHP sleep | 30.0 | 30.9 | 18 | 23.3 | 28.49 | 18 | 2.06 | .055 | 0.2 | 21.3 | 29.7 | 14 | .52 | .610 | 0.3 |
M mean, sd standard deviation, n sample size, T t-value in t-test for repeated measurements, p level of statistical significance, d Cohen’s d, HADS Hospital anxiety and depression Scale, SCL-90-R Symptom Checklist-90-Revised, FSS Fatigue Severity Scale, SF-36 Short Form 36, PCS-36 physical health summary scale of SF-36, MCS-36 mental health summary scale of SF-36, NHP Nottingham Health Profile
aData from 1 patient of the first cohort is missing
bData from up to 4 patients is missing
Fig. 1Admission-discharge and admission-follow-up effect sizes for psychological assessments with statistically significant admission-discharge improvements. Cohen’s d: effect size; HADS: Hospital anxiety and depression Scale; SCL-90-R: Symptom Checklist-90-Revised; FSS: Fatigue Severity Scale; SF-36: Short Form 36; MCS-36: mental health summary scale of SF-36; NHP: Nottingham Health Profile